

**Margaret Reynolds**  
Government Affairs Principal



March 24, 2022

6625 W 78<sup>th</sup> Street  
Edina, MN 55439

TO: Members of the House Health Finance and Policy Committee  
RE: House File 1516

651-341-3161

Dear Chair Lieblich and Members of the Committee,

Cigna Corporation is a global health service company dedicated to improving the health, well-being and peace of mind of those they serve. Cigna delivers choice, predictability, affordability and access to quality care through integrated capabilities and connected, personalized solutions that advance whole person health. All products and services are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth, and Express Scripts. Such products and services include an integrated suite of health services, such as medical, dental, behavioral health, pharmacy, vision, supplemental benefits, and other related products. Cigna maintains sales capability in over 30 countries and jurisdictions, and has more than 175 million customer relationships throughout the world. Cigna has 1,911 employees based here in Minnesota.

We respectfully oppose House File 1516 as it is currently drafted. I do want to thank Rep. Schultz for keeping an open dialogue with me over the past few years as I have expressed my concerns with the bill. I appreciate her willingness to listen and engage in conversation.

In Section 1, Subd. 2, clause (b), the bill mandates that a PBM or health carrier must elect "equivalent coverage" for all biologics, biosimilars, or interchangables if we choose to elect coverage of one of these products. This takes away the ability for us to utilize our formulary and tier products based on the lowest net-cost to our plan participants. The term "equivalent coverage" (line 2.4) would have the PBM and the Plan charging the same cost-sharing amount for a reference biologic and biosimilar or interchange to the patient, regardless of the list price or any other price concessions that may be achieved through negotiations with the manufacturer.

I would appreciate the opportunity to continue working with the author to improve this bill. By maintaining our ability to have a formulary, we can ensure safe, accessible, affordable prescription drugs.

Sincerely,

Margaret Reynolds  
Government Affairs Principal